Last10K.com

Angiodynamics Inc (ANGO) SEC Filing 10-K Annual Report for the fiscal year ending Tuesday, May 31, 2022

SEC Filings

ANGO Annual Reports

Angiodynamics Inc

CIK: 1275187 Ticker: ANGO
Exhibit 99.1


PRESS RELEASE
Investor Contact:

AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408
AngioDynamics Reports Fiscal Year 2022 Fourth Quarter
and Full-Year Financial Results;
Issues Fiscal Year 2023 Guidance
Fiscal Year 2022 Fourth Quarter Highlights
Net sales of $87.0 million increased 13.2% compared to the prior-year quarter
Gross margin of 53.4% declined 170 basis points year over year
GAAP loss per share of $0.16 and adjusted earnings per share of $0.01
Cash and cash equivalents at May 31, 2022 were $28.8 million

Full-Year 2022 Highlights
Net sales of $316.2 million increased 8.7% year over year
Gross margin declined 150 basis points year over year to 52.4%
GAAP loss per share of $0.68 and adjusted earnings per share of $0.00

Latham, New York, July 12, 2022  AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2022, which ended May 31, 2022.

“Our strong performance during the quarter, driven by our Med Tech portfolio, is a direct result of the continued hard work and commitment of our AngioDynamics team,” commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. “We delivered on the strategic objectives for fiscal year 2022 that we laid out a year ago during our Investor and Technology Day while managing through a number of macro-related headwinds, including supply chain disruptions and ongoing inflationary

The following information was filed by Angiodynamics Inc (ANGO) on Tuesday, July 12, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Angiodynamics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Angiodynamics Inc.

Continue

Assess how Angiodynamics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Angiodynamics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Other
Filter Subcategory:
All
Cash Flow
Product
Expense
Debt
Income
Earnings
Shares
Other
Inside Angiodynamics Inc's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Audit Information
Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Comprehensive Income (Loss)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Accrued Liabilities
Accrued Liabilities (Details)
Accrued Liabilities (Tables)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) (Details)
Accumulated Other Comprehensive Income (Loss) (Tables)
Acquisition, Restructuring And Other Items, Net
Acquisition, Restructuring And Other Items, Net (Tables)
Acquisition, Restructuring And Other Items, Net - Narrative (Details)
Acquisition, Restructuring And Other Items, Net - Schedule (Details)
Acquisitions
Acquisitions (Tables)
Acquisitions - Aggregate Purchase Price (Details)
Acquisitions - Narrative (Details)
Basis Of Presentation, Business Description And Summary Of Significant Accounting Policies
Basis Of Presentation, Business Description And Summary Of Significant Accounting Policies (Details Textual)
Basis Of Presentation, Business Description And Summary Of Significant Accounting Policies (Policies)
Basis Of Presentation, Business Description And Summary Of Significant Accounting Policies (Tables)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Narrative (Details)
Commitments And Contingencies - Schedule (Details)
Earnings Per Share
Earnings Per Share (Details)
Earnings Per Share (Tables)
Fair Value Of Financial Instruments
Fair Value Of Financial Instruments Fair Value Of Financial Instruments (Details 2)
Fair Value Of Financial Instruments Fair Value Of Financial Instruments (Details 3)
Fair Value Of Financial Instruments Fair Value Of Financial Instruments (Details)
Fair Value Of Financial Instruments Fair Value Of Financial Instruments (Tables)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (Tables)
Goodwill And Intangible Assets - Expected Future Amortization Expense (Details)
Goodwill And Intangible Assets - Intangible Assets (Details)
Goodwill And Intangible Assets - Narrative (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Components Of Loss (Details)
Income Taxes - Deferred Tax Assets And Liabilities (Details)
Income Taxes - Income Tax Benefit (Details)
Income Taxes - Income Tax Rate Reconciliation (Details)
Income Taxes - Narrative (Details)
Income Taxes Income Taxes - Reconciliation Of Unrecognized Tax Benefits (Details)
Inventories
Inventories (Details)
Inventories (Tables)
Leases
Leases (Details)
Leases (Tables)
Leases - Liability Maturity Schedule (Details)
Leases - Supplemental Balance Sheet Information (Details)
Leases - Supplemental Cash Flow Information (Details)
Leases - Supplemental Statement Of Operations Information (Details)
Long Term Debt
Long Term Debt - Narrative (Details)
Prepaid Expenses And Other
Prepaid Expenses And Other (Details)
Prepaid Expenses And Other (Tables)
Property, Plant And Equipment, Net
Property, Plant And Equipment, Net (Tables)
Property, Plant, And Equipment, Net (Details)
Retirement Plans
Retirement Plans (Details)
Revenue From Contracts With Customers
Revenue From Contracts With Customers (Details)
Revenue From Contracts With Customers (Tables)
Revenue From Contracts With Customers - Disaggregation Of Revenue (Details)
Revenue From Contracts With Customers Revenue From Contracts With Customers - Contract Assets And Liabilities (Details)
Segments And Geographic Information
Segments And Geographic Information (Tables)
Segments And Geographic Information - Narrative (Details)
Segments And Geographic Information - Sale For Geographic Areas (Details)
Segments And Geographic Information - Sales By Product Category (Details)
Stockholders' Equity
Stockholders' Equity (Details 2)
Stockholders' Equity (Details)
Stockholders' Equity (Tables)
Stockholders' Equity - Compensation Expense (Details)
Stockholders' Equity - Narrative (Details)
Valuation And Qualifying Accounts
Valuation And Qualifying Accounts (Details)
Ticker: ANGO
CIK: 1275187
Form Type: 10-K Annual Report
Accession Number: 0001275187-22-000017
Submitted to the SEC: Fri Jul 22 2022 3:01:59 PM EST
Accepted by the SEC: Fri Jul 22 2022
Period: Tuesday, May 31, 2022
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ango/0001275187-22-000017.htm